Drug development remains one of the most challenging and inefficient industries. It takes more than a decade and roughly $2.3 billion to get a treatment to market, and still, 90% of drugs tested never make it to patients.
Paris-based health tech startup ArcaScience thinks it has found a way to change that. The company has raised a $7 million seed round, led by The Moon Venture with participation from Pléiade Venture, Plug & Play Ventures, Bpifrance, and AKKA Technologies, to bring its AI-driven benefit–risk intelligence platform to new markets. The funding will support expansion into the U.S. and U.K., along with the launch of its first patient-facing product, with early applications in pediatric brain cancer and dermatology.
ArcaScience founders told TFN, “ArcaScience is the first AI solution to produce an instant drug’s benefit-risk analysis. We’ve built a proprietary platform powered by several specialised AI models trained on 100 billion data points. What used to take months of manual review can now be analysed in days, supporting teams with faster, more confident decision-making.”
Born from a founder’s journey
ArcaScience was founded by Romain Clement, a former scientific data program lead at GSK and an academic at the Sorbonne and Stanford. Clement’s motivation came after a personal diagnosis of brain cancer. Following his remission, he turned his frustration with the inefficiencies of treatment design into a company aimed at fixing them.
“After his remission, he took it upon himself to address the vast and numerous blind spots in how pharmaceutical companies evaluate the benefit-risk profile of new drugs. Founded to address this critical bottleneck in drug development, ArcaScience has pioneered the development of AI to radically improve benefit-risk assessments for pharmaceuticals & regulators, empowering both clinical teams and patients,” explain ArcaScience founders to TFN.
Clement later teamed up with serial entrepreneur Jean-François Arbona and former Happytal/La Poste Santé executive Julien Dufour to drive commercial growth. The company today employs an internationally diverse team, with more than 60% of staff hailing from outside France and women making up over a third of its workforce.
A new standard for benefit-risk intelligence
ArcaScience’s edge is speed and scope. The company’s platform applies 24 specialised AI models to a database of 100 billion biomedical datapoints, spanning everything from clinical trial results to post-market patient records. That breadth enables near-instant drug benefit–risk assessments: work that usually takes months of manual data review.
The startup already counts Sanofi, AstraZeneca, GSK, Takeda, ICON, and the Paris Brain Institute among its early customers, with its software supporting more than 70,000 patients in chronic disease research. During the COVID-19 pandemic, the platform was utilised by the French government to organise and analyse the full scientific literature on the pandemic.
The competitive field isn’t empty: IQVIA, Parexel, Thermo Fisher, and Prometria offer their own pharmacovigilance and trial-optimisation tools. ArcaScience, however, argues that its ability to track drug data continuously gives it a key advantage.
What’s next?
Unlike many startups at the seed stage, ArcaScience says it has already reached break-even twice since late 2024. The new capital will be allocated toward hiring a Chief Medical Officer, strengthening partnerships with global pharmaceutical companies, and enhancing the company’s patient-facing interface.
Over the next five years, ArcaScience aims to evolve from a tool into a global industry standard, catalysing a fundamental shift in how drugs are developed and monitored. With concrete success already proven through collaborations with leading pharmaceutical companies, participation in European AI-driven pediatric cancer consortia, and support for more than 70,000 patients to date, the company plans to extend its transformative impact globally.
“We believe that patients deserve better than the inefficiencies of today’s system, where most therapies fail before reaching the people who need them, for the wrong reasons. By utilising global biomedical data with a novel type of AI, we are establishing a new standard for designing, assessing, and monitoring treatments, from clinical trials to real-world use,” conclude ArcaSceince founders.
